Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (pathological committee for optimal use of trastuzumab)

Breast Cancer

Volumn 8, Issue 4, 2001, Pages 316-320

  Umemura, Shinobu ^a   Sakamoto, Goi ^b   Sasano, Hironobu ^c   Tsuda, Hitoshi ^d   Akiyama, Futoshi ^b   Kurosumi, Masafumi ^e   Tokuda, Yutaka ^a   Watanabe, Toru ^f   Toi, Masakazu ^g   Hasegawa, Tadashi ^h   Yoshiyuki Osamura, R ^a  

^a TOKAI UNIVERSITY   (Japan)

^b CANCER INSTITUTE   (Japan)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^e SAITAMA CANCER CENTER   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

^g TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^h NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Breast cancer; Fish; Guideline; HER2; Immunohistochemistry; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TRASTUZUMAB;

BREAST TUMOR; CANCER STAGING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; NEEDLE BIOPSY; PATHOLOGY; PRACTICE GUIDELINE; PROTO ONCOGENE; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; BIOPSY, NEEDLE; BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM METASTASIS; NEOPLASM STAGING; PRACTICE GUIDELINES; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 0035755277     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967531     Document Type: Conference Paper

References (38)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987. (Pubitemid 17231334)
2. Seshadri R, Firgaira FA, Horsfall DJ, et al: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11:1936-1942, 1993. (Pubitemid 23304619)
3. Paik S, Bryant J, Park C, et al: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998. (Pubitemid 28439960)
4. Thor AD, Berry DA, Budman DR, et al: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90:1346-1360, 1998. (Pubitemid 28439959)
5. Leitzel K, Teramoto Y, Konrad K, et al: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129-1135, 1995.
6. Yamauchi H, O'Neill A, Gelman R, et al: Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15:2518-2525, 1997. (Pubitemid 27289880)
7. Allred DC, Clark GM, Tandon AK, et al: HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992.
8. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049-1056, 1992.
9. Schubert D, Heinemann S, Carlisle W, et al: Clonal cell lines from the rat central nervous system. Nature 249:224-227, 1974.
10. Shih C, Padhy LC, Murray M, et al: Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290:261-264, 1981. (Pubitemid 11149660)
11. Coussens L, Yang-Feng TL, Liao YC, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139, 1985. (Pubitemid 16169997)
12. Semba K, Kamata N, Toyoshima K, et al: A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82:6497-6501, 1985. (Pubitemid 16230541)
13. Yamamoto T, Ikawa S, Akiyama T, et al: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319:230-234, 1986. (Pubitemid 16128786)
14. Fukushige S, Matsubara K, Yoshida M, et al: Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 6:955-958, 1986. (Pubitemid 16135959)
15. Schechter AL, Hung MC, Vaidyanathan L, et al: The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229:976-978, 1985. (Pubitemid 16248489)
16. Jones JT, Akita RW, Sliwkowski MX: Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 447:227-231, 1999. (Pubitemid 29146091)
17. Guy PM, Platko JV, Cantley LC, et al: 3rd Insect cellexpressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 91:8132-8136, 1994.
18. Alimandi M, Romano A, Curia MC, et al: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813-1821, 1995.
19. Wallasch C, Weiss FU, Niederfellner G, et al: Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 14:4267-4275, 1995.
20. Pinkas-Kramarski R, Soussan L, Waterman H, et al: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452-2467, 1996. (Pubitemid 26151185)
21. Chausovsky A, Waterman H, Elbaum M, et al: Molecular requirements for the effect of neuregulin on cell spreading, motility and colony organization. Oncogene 19:878-888, 2000. (Pubitemid 30153745)
22. Hynes NE, Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165-184, 1994.
23. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137, 2001. (Pubitemid 33674041)
24. Lewis GD, Figari I, Fendly B, et al: Differential responses of human tumor cell lines to anti-pl85HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255-263, 1993. (Pubitemid 23300507)
25. Carter P, Presta L, Gorman CM, et al: Humanization of an anti-pl85HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289, 1992.
26. Tokuda Y, Ohnishi Y, Shimamura K, et al: In vitro and in vivo anti-tumour effects of a humanized monoclonal antibody against c-erbB-2 product. Br J Cancer 73:1362-1365, 1996. (Pubitemid 26175668)
27. Pegram MD, Baly D, Wirth C, et al: Antibody dependant cell-mediated cytotoxicity in breast cancer patients in phase II clinical trials of a humanized anti-HER2 antibody. Proc Am Assoc Cancer Res Annu Meet 38:A4044, 1997.
28. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999. (Pubitemid 29415219)
29. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001. (Pubitemid 32222155)
30. ® pivotal trials. Proc Am SOc Clin Oncol 19:75a, 2000.
31. Jacobs TW, Gown AM, Yaziji H, et al: Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17:1974-1982, 1999. (Pubitemid 29318824)
32. Ridolfi RL, Jamehdor MR, Arber JM: HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 13:866-873, 2000. (Pubitemid 30643834)
33. Pauletti G, Dandekar S, Rong H, et al: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651-3664, 2000.
34. Lebeau A, Deimling D, Kaltz C, et al: Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19:354-363, 2001. (Pubitemid 32112846)
35. Kakar S, Puangsuvan N, Stevens JM, et al: HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn 5:199-207, 2000.
36. Vogel C, Cobleigh M, Tripathy D, et al: First-line, nonhormonal, treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (Trastuzumab, humanized anti-HER2 antibody). Proc Am Soci Clin Oncol 19:71a, 2000.
37. Vogel C, Cobleigh M, Tripathy D, et al: Superior outcomes with Herceptin (trastuzumab) (H) in fluorescence in situ hybridization (FISH)-selected patients. Am Soci Clin Oncol 20:22a, 2001.
38. Seidman AD, Fornier MN, Esteva FJ, et al: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587-2595, 2001. (Pubitemid 32441364)